Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide: 40 years on.

G E Diggle

    International Journal of Clinical Practice
    |January 5, 2002
    PubMed
    Summary

    Thalidomide, initially a sedative, caused severe birth defects but later showed efficacy in treating leprosy complications and other immune-related conditions. Its antiangiogenic properties also led to trials in cancer, culminating in its 1998 FDA approval.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The toxic oil syndrome: 20 years on.

    International journal of clinical practice·2001
    Same author

    Carcinogens in food: priorities for regulatory action.

    Human & experimental toxicology·1996
    Same author

    The toxic oil syndrome: a continuing challenge.

    Adverse drug reactions and toxicological reviews·1995
    Same author

    Risk assessment and natural toxins.

    Natural toxins·1992
    Same author

    Carcinogenic drugs.

    Adverse drug reactions and acute poisoning reviews·1988
    Same author

    A survey of products licensed in the United Kingdom from 1971-1981.

    British journal of clinical pharmacology·1981

    Area of Science:

    • Pharmacology
    • Teratology
    • Immunology
    • Oncology

    Background:

    • Thalidomide was withdrawn globally in 1961 due to its teratogenic effects causing congenital malformations.
    • Despite its tragic history, thalidomide's therapeutic potential was rediscovered in 1965 for erythema nodosum leprosum.
    • Its mechanism of action, particularly its teratogenicity and immunosuppressive effects, remains incompletely understood.

    Purpose of the Study:

    • To explore the multifaceted therapeutic applications of thalidomide beyond its initial sedative use.
    • To investigate thalidomide's efficacy in various immunological disorders and its antiangiogenic properties.
    • To review the historical context and regulatory journey of thalidomide, including its eventual FDA approval.

    Main Methods:

    • Literature review of historical data and clinical studies on thalidomide.
    • Analysis of case reports and experimental trials investigating thalidomide's effects.
    • Examination of regulatory decisions and public health implications.

    Main Results:

    • Thalidomide demonstrated efficacy in treating erythema nodosum leprosum, Behçet's syndrome, graft-versus-host disease, and aphthous ulceration in HIV-positive patients.
    • Antiangiogenic properties were confirmed, leading to trials in malignant conditions, with promising results in multiple myeloma.
    • Despite concerns regarding its teratogenicity and use in immunocompromised patients, thalidomide received FDA marketing approval in 1998.

    Conclusions:

    • Thalidomide is a drug with a complex history, exhibiting both severe teratogenic risks and significant therapeutic benefits.
    • Its immunosuppressive and antiangiogenic activities support its use in a range of conditions, necessitating careful risk-benefit assessment.
    • The re-approval of thalidomide highlights the importance of ongoing research into its mechanisms and applications, alongside stringent regulatory control.

    Related Experiment Videos